|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||158.07 - 160.84|
|52 Week Range||116.24 - 161.39|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||34.07|
|Earnings Date||Feb 10, 2020 - Feb 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||164.87|
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories and Fios Genomics have entered into an exclusive partnership for bioinformatics-driven discovery and safety assessment
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River and Takeda announce a multi-year drug discovery collaboration to identity and develop preclinical candidates.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The IBD SmartSelect Composite Rating for Charles River Labs International rose from 93 to 96 Tuesday.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of HemaCare Corporation ("HemaCare" or the "Company") (OTCMKTS: HEMA) in connection with the proposed acquisition of the Company by Charles River Laboratories International, Inc. (NYSE: CRL). Under the terms of the acquisition agreement, HEMA shareholders will receive $25.40 per share in cash. The deal is scheduled to close in the first quarter of 2020.
Rowley Law PLLC is investigating potential securities law violations by HemaCare Corporation (OTCMKTS: HEMA) and its board of directors concerning the proposed acquisition of the company by Charles River Laboratories International, Inc. (NYSE: CRL). Stockholders will receive $25.40 per share of HemaCare Corporation common stock that they hold. The transaction is valued at approximately $380 million and is expected to close in the first quarter of 2020.
Charles River Laboratories to acquire HemaCare, a leader in the production of human-derived cellular products for the cell therapy market
Charles River has entered a strategic partnership with Bit Bio, increasing translational drug discovery technologies.
Three years after buying 466 Devon Park Drive in Wayne for under $10 million, Maquire Hayden has put the 155,200-square-foot building up for sale and one estimate has it trading for upwards of $50 million. When Maguire Hayden bought the building from Merck & Co. for $7.9 million, the building, which has about 72,000 square feet of lab and related space, was vacant. The building was developed in 1975 and Maguire Hayden then launched an interior and exterior renovation of the building.
Today, Charles River announced the launch of Distributed Bio's Cosmic antibody library, providing their clients exclusive access.
Charles River updates cancer model database to add over 100 new tumor models and 150 new bioinformatic data sets, increasing translational power.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
The contract research company's shares will not stay in a tight trading range indefinitely, so would-be buyers should be prepared to act.
Charles River Laboratories International, Inc. announced today that it will present at three upcoming investor conferences, including:
Charles River (CRL) delivered earnings and revenue surprises of 3.05% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?